Logo image of ARCT

ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Fundamental Analysis

USA - NASDAQ:ARCT - US03969T1097 - Common Stock

21.03 USD
+0.57 (+2.79%)
Last: 9/22/2025, 7:21:00 PM
21.33 USD
+0.3 (+1.43%)
After Hours: 9/22/2025, 7:21:00 PM
Fundamental Rating

4

ARCT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ARCT as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ARCT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARCT has reported negative net income.
ARCT had a negative operating cash flow in the past year.
In the past 5 years ARCT reported 4 times negative net income.
ARCT had negative operating cash flow in 4 of the past 5 years.
ARCT Yearly Net Income VS EBIT VS OCF VS FCFARCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

ARCT has a Return On Assets of -19.45%. This is in the better half of the industry: ARCT outperforms 76.95% of its industry peers.
Looking at the Return On Equity, with a value of -26.04%, ARCT belongs to the top of the industry, outperforming 80.11% of the companies in the same industry.
Industry RankSector Rank
ROA -19.45%
ROE -26.04%
ROIC N/A
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ARCT Yearly ROA, ROE, ROICARCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

ARCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCT Yearly Profit, Operating, Gross MarginsARCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARCT has more shares outstanding
ARCT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARCT Yearly Shares OutstandingARCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ARCT Yearly Total Debt VS Total AssetsARCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 2.63 indicates that ARCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
ARCT's Altman-Z score of 2.63 is fine compared to the rest of the industry. ARCT outperforms 69.33% of its industry peers.
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.63
ROIC/WACCN/A
WACC9.84%
ARCT Yearly LT Debt VS Equity VS FCFARCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.90 indicates that ARCT has no problem at all paying its short term obligations.
ARCT has a better Current ratio (5.90) than 62.27% of its industry peers.
ARCT has a Quick Ratio of 5.90. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
ARCT's Quick ratio of 5.90 is fine compared to the rest of the industry. ARCT outperforms 62.45% of its industry peers.
Industry RankSector Rank
Current Ratio 5.9
Quick Ratio 5.9
ARCT Yearly Current Assets VS Current LiabilitesARCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

ARCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.23%, which is quite good.
Looking at the last year, ARCT shows a very negative growth in Revenue. The Revenue has decreased by -25.46% in the last year.
Measured over the past years, ARCT shows a very strong growth in Revenue. The Revenue has been growing by 48.91% on average per year.
EPS 1Y (TTM)13.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.88%
Revenue 1Y (TTM)-25.46%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-43.24%

3.2 Future

ARCT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.82% yearly.
ARCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.37% yearly.
EPS Next Y13.95%
EPS Next 2Y-2.27%
EPS Next 3Y27.52%
EPS Next 5Y37.82%
Revenue Next Year-42.59%
Revenue Next 2Y-13.97%
Revenue Next 3Y10.27%
Revenue Next 5Y26.37%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARCT Yearly Revenue VS EstimatesARCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ARCT Yearly EPS VS EstimatesARCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCT Price Earnings VS Forward Price EarningsARCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCT Per share dataARCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

ARCT's earnings are expected to grow with 27.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.27%
EPS Next 3Y27.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCTURUS THERAPEUTICS HOLDIN

NASDAQ:ARCT (9/22/2025, 7:21:00 PM)

After market: 21.33 +0.3 (+1.43%)

21.03

+0.57 (+2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners91.62%
Inst Owner Change-2.84%
Ins Owners0.81%
Ins Owner Change0%
Market Cap570.96M
Analysts87.06
Price Target66.07 (214.17%)
Short Float %21.62%
Short Ratio9.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.16%
Min EPS beat(2)61.7%
Max EPS beat(2)62.62%
EPS beat(4)3
Avg EPS beat(4)26.29%
Min EPS beat(4)-98.22%
Max EPS beat(4)79.04%
EPS beat(8)7
Avg EPS beat(8)39.56%
EPS beat(12)10
Avg EPS beat(12)236.3%
EPS beat(16)12
Avg EPS beat(16)178.2%
Revenue beat(2)2
Avg Revenue beat(2)15.02%
Min Revenue beat(2)9.67%
Max Revenue beat(2)20.36%
Revenue beat(4)3
Avg Revenue beat(4)-2.09%
Min Revenue beat(4)-50.01%
Max Revenue beat(4)20.36%
Revenue beat(8)6
Avg Revenue beat(8)49.54%
Revenue beat(12)9
Avg Revenue beat(12)68.63%
Revenue beat(16)10
Avg Revenue beat(16)114.11%
PT rev (1m)9.12%
PT rev (3m)9.62%
EPS NQ rev (1m)3.89%
EPS NQ rev (3m)21.08%
EPS NY rev (1m)0%
EPS NY rev (3m)18.07%
Revenue NQ rev (1m)10.25%
Revenue NQ rev (3m)3.28%
Revenue NY rev (1m)1.68%
Revenue NY rev (3m)1.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.68
P/FCF N/A
P/OCF N/A
P/B 2.47
P/tB 2.47
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-3.15
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS4.5
BVpS8.51
TBVpS8.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.45%
ROE -26.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.55%
Cap/Sales 0.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.9
Quick Ratio 5.9
Altman-Z 2.63
F-Score2
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)207.21%
Cap/Depr(5y)221.18%
Cap/Sales(3y)1.97%
Cap/Sales(5y)10.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.88%
EPS Next Y13.95%
EPS Next 2Y-2.27%
EPS Next 3Y27.52%
EPS Next 5Y37.82%
Revenue 1Y (TTM)-25.46%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-43.24%
Revenue Next Year-42.59%
Revenue Next 2Y-13.97%
Revenue Next 3Y10.27%
Revenue Next 5Y26.37%
EBIT growth 1Y18.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.27%
EBIT Next 3Y1.8%
EBIT Next 5YN/A
FCF growth 1Y-151.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-148.9%
OCF growth 3YN/A
OCF growth 5YN/A